Compare IDEXX Laboratories, Inc. (IDXX) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Newmont Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Newmont Corporation trades at $117.84 (market cap $121.75B). The key difference: Newmont Corporation is far larger — about 3× IDEXX Laboratories, Inc.'s market cap, and Newmont Corporation pays a 0.9% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Newmont Corporation for 58 Days on average.
| IDXX | NEM | |
|---|---|---|
Market Cap | $40.43B | $121.75B |
Volume | 692,164 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $135.14 |
52-Week Low | $504.70 | $78.63 |
Typical Hold Time | 46 Days | 58 Days |
Enterprise Value | $41.32B | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Newmont Corporation (NEM) trades at $115.55, up 1.77% with strong fundamental performance including record free cash flow of $5.3B in H1 2026 and three consecutive earnings beats. The stock shows bearish technical signals despite solid valuation metrics with P/E of 14.57 and ROE of 25.53%. Recent news highlights operational improvements and gold price support driving per-share growth initiatives.
NEM presents a compelling value opportunity with strong analyst consensus (75.68% buy rating) and $136.83 price target representing 18% upside. Key risks include gold price volatility and execution of growth projects, but robust cash flow generation and improving margins support long-term shareholder value creation in the current gold market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
